Cellular response to chemotherapy and radiation in cervical cancer

Transcription

1 American Journal of Obstetrics and Gynecology (2005) 192, Cellular response to chemotherapy and radiation in cervical cancer Angela Saxena, MD, Catheryn Yashar, MD, Douglas D. Taylor, PhD, Cicek Gercel-Taylor, PhD* Department of Obstetrics, Gynecology and Women s Health and Department of Radiation Oncology, University of Louisville School of Medicine, Louisville, Ky Received for publication September 1, 2004; accepted December 9, 2004 KEY WORDS Cervical cancer Radiotherapy Cisplatin Paclitaxel 5-fluorouracil Effect of irradiation alone and irradiation after 5-fluorouracil (5-FU), paclitaxel, or cisplatin (CDDP) was investigated in human cervical cell lines (CaSki, ME180, SiHa, and C33A). Highrisk human papillomavirus (HPV) (C) CaSki and SiHa cells were the most resistant to CDDP, 5-FU, and radiation treatments. Radiation and CDDP and 5-FU resulted in decreased survival of HPV 16 and 18 (C) cells, whereas addition of paclitaxel to radiation treatments decreased killing. Enhanced killing of ME180 cells containing HPV39 sequences was demonstrated with chemoradiotherapy with all agents. HPV( ) C33A was more sensitive to radiation than the other cell lines, and the addition of chemotherapeutic agents did not result in significant change in cytotoxicity. Expression of survivin was inversely proportional to cell sensitivity to CDDP, 5-FU, and radiation. Constitutive AKT levels are the lowest in cell lines that are the most resistant to CDDP, 5-FU, and radiation. These data provide correlation of response to combined therapeutic modalities with HPV status of cervical cancer and expression of survivin and AKT. Ó 2005 Elsevier Inc. All rights reserved. Cervical cancer is one of the major causes of cancer death worldwide. Particular human papillomavirus (HPV) types are carcinogenic in humans and more than 99% of cervical cancers are initiated by HPV infection. Genital HPV types are divided into high-, medium-, and low-risk groups based on the frequency of association with malignant tumors. 1 * Reprint requests: Cicek Gercel-Taylor, PhD, University of Louisville, School of Medicine, Department of Obstetrics, Gynecology and Women s Health, 511 S Floyd St, Room 416, Louisville, KY Treatment of invasive cancer involves management of the primary lesion and sites of metastatic disease. Surgery and radiation therapy may be used for primary treatment, although definitive surgery is usually limited to patients with stages I or early IIa disease. Currently chemoradiotherapy involving cisplatin (CDDP) and 5- fluorouracil (5-FU) is the standard of care. 2 However, improvement in the treatment of locally advanced disease is needed. Resistance of cancer to radiotherapy is a primary cause of treatment failure. Drug combinations eliminating radiation or CDDP-resistant cells may improve local control rates. 3 The radiosensitivity of tumor cells is measured in vitro by clonogenic survival. 4 Because this assay is time /$ - see front matter Ó 2005 Elsevier Inc. All rights reserved. doi: /j.ajog

2 1400 Saxena et al Figure 1 A-C, Chemosensitivity of cervical cancer cells (C33A, CaSki, ME180, SiHa) cells to CDDP, 5-FU, and Tax. SRB assay was used to generate the survival curves with assays run in quadruplicate twice. Results are shown as mean G SEM. and resources consuming, there is interest in assessing nonclonogenic endpoints for measuring tumor radiosensitivity and individualization of treatment. 5 This study investigates an association between HPV status of cervical cancer cells and their sensitivity to chemotherapeutic agents (5-FU, paclitaxel [Tax], CDDP), and radiation. Constitutive expression of p53, p73, survivin, mcl-1, and AKT was studied in these cell lines. Material and methods Cell lines CaSki (HPV-16, 18), C33A (HPV negative), SiHa (HPV-18), and ME180 (HPV-39) cells were used. All cell lines were cultured in RPMI medium supplemented with charcoal-treated 10% fetal bovine serum, at 37(C in a humidified CO 2 incubator. Determination of cell survival Chemotherapy survival was performed by the sulforhodamine B (SRB) assays. Cells (1!10 3 ) were plated in quadruplicate and cultured overnight. Drugs were added for 2 hours. Cells were incubated for 96 hours and stained with SRB for quantitation at 540 nm. Radiation survival was determined by the clonogenic ability by adding 500 cells in triplicate (0, 100, and 200 cgy), or 1000 cells (500 and 800 cgy). Colonies containing more than 50 cells were scored. When radiation was combined with chemotherapy, cells were pretreated with drugs for 4 (CDDP,

3 Saxena et al FU), or 16 hours (Tax). Ratio of surviving cells with radiation alone (500 cgy) was compared with combination of radiation and chemotherapy. Analysis of variance was used for statistical analysis. Radiation Cells were irradiated with 4 mv photons with a Phillips linear accelerator (Phillips Medical Systems, Andover, Mass) with an appositional beam at 100 cm SSD with 1 cm of tissue-equivalent lucite bolus in a field size of 39! 39 cm. Cells were positioned at central axis with a machine dose rate of approximately 400 cgy min ÿ1. Western blot analysis Cells were harvested in lysis buffer and samples (40 mg) were electrophoresed on 8% to 16% polyacrylamide gradient gels. Proteins were transferred to nitrocellulose, blocked with 5% nonfat dry milk, and probed with antibodies to mcl-1, survivin, AKT, pakt (Thr 308), pakt (Ser 473), p53, and p73. Peroxidase-labeled secondary antibody was used, and immunoreactive bands were visualized with electrochemoluminescent. Results Differences in response to the chemotherapeutic agents were observed in the 4 cell lines. CDDP and 5-FU sensitivity were similar in SiHa and CaSki as the most resistant cells, followed by ME180 cells. SiHa and CaSki were resistant to CDDP and 5-FU, followed by ME180. C33A cells were most sensitive to both CDDP and 5-FU (Figure 1, A and B). The most resistant cell line to Tax was ME180, followed by SiHa, C33A, and CaSki (Figure 1, C). The C33A cell line was the most sensitive to radiation with the other 3 cell lines displaying similar survival (Figure 2). There was 50% survival at 200 cgy with C33A cells being the most sensitive. The other cell lines had 50% survival at doses from 370 cgy to 420 cgy. For the chemoradiotherapy experiments, radiation was administered at 500 cgy, whereas chemotherapeutic agents (CDDP, Tax, and 5-FU) were given at an LD 30 concentration (Figure 3). The most cytotoxic chemoradiation regimen was CDDP and 5-FU in CaSki and SiHa cells, containing high-risk HPV. Tax was not effective in these 2 cell lines. ME180 cells demonstrated higher cell kill with combination than chemotherapy alone. Combination of drugs and radiation did not enhance the sensitivity of C33A cells. Expression of gene products AKT, the 2 forms of phosphorylated AKT, mcl-1, survivin, and p53 were studied. p53 expression was demonstrated in the HPVnegative C33A cells and ME180 cells, but was minimal in the other cell lines (data not shown). There was no Figure 2 Radiation survival curve of cervical cancer cells (C33A, CaSki, ME180, SiHa). Colony formation assay was used to determine survival. The assays were performed twice in triplicate. correlation with the expression of mcl-l, p73, and phosphorylated forms of AKT and sensitivity of these cell lines. Survivin expression correlated with the HPV- 16 and 18 expression in the CaSki and SiHa cells and the pattern of resistance to CDDP and 5-FU (Figure 4). Constitutive expression of AKT was the lowest in SiHa and CaSki cells with high-risk HPV sequences. Comment Radiotherapy is the treatment of choice for patients with locally advanced cervical carcinoma resulting in progression-free survival rates of 70%. 6 To increase local control rates, chemotherapeutic agents are being incorporated into the treatment protocols. We conducted this study to determine the effectiveness of the 3 chemotherapeutic agents that have been used in combination with radiation in cervical and other solid tumors. We demonstrate that HPV-16 or 18-containing cell lines were the most resistant to CDDP and 5-FU, whereas the cell line that was HPV negative (C33A) was the most sensitive. HPV-dependent inactivation of apoptotic regulators such as p53 might result in the cellular survival advantage provided by high-risk HPV that showed low expression in these cell lines, higher in HPV 39 (C) ME180 and HPV (ÿ) C33A. With combined treatments, CDDP and 5-FU were effective in enhancing the cytotoxic effect of both modalities in the HPV(C) CaSki, SiHa, and ME180 cells. Tax resulted in lessening of the radiation effect. Other investigators have demonstrated no radiosensitizing effect of Tax with ZMK-1, CaSki, and MCF-7 cells. 7,8 HPV(ÿ) C33A cell survival was not affected by multimodality therapy but demonstrated significant sensitivity to each agent separately. The question of whether HPV ( ) tumors would be better served by sequential therapy to reduce toxicity needs to be studied.

4 1402 Saxena et al Figure 3 Effect of radiation and chemotherapeutic agents on cervical cancer cells (C33A, CaSki, ME180, SiHa). Radiation dose used in these experiments was 500 cgy alone or in combination with LD 30 dose of CDDP, 5-FU, or Tax. Colony formation assay was used to determine survival. Asterisks, significantly less surviving colonies from radiation alone, P!.05. Figure 4 Western immunoblot analysis of expression of survivin and AKT in cervical cancer cell lysates. Study of the markers of survival demonstrated that survivin expression correlated with drug resistance in CaSki and SiHa cells similar to a previous study in colorectal cells. 9 Survivin is a member of the inhibitors of apoptosis protein (IAP) family that is involved in control of cell division and inhibition of apoptosis. Survivin has been shown to be expressed in most human neoplasms and is associated with clinical progression. 10 Clinical data on survivin and AKT expression may be helpful in elucidation of the potential role of these gene products as markers of therapeutic response. Other groups have suggested that concomitant CDDP/radiotherapy regimens may result in higher level of local tumor control through additive toxicity and not radiosensitization. No correlation between the cellular sensitivities to CDDP and radiation were demonstrated. Our study suggests that the effect of CDDP or other chemotherapeutic agents is likely to be compromised in tumors bearing high-risk HPV, an observation that could have profound clinical implications. It appears that radiation partially reverses this resistance; however, other chemotherapeutic agents may afford greater cell kill. Additional studies with varying concentrations and

A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven

Mechanism of action The word cancer refers to a number of different diseases that share a common trait: the rapid, unrestrained growth and spread of cells that can invade and destroy surrounding tissues,

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer Ryan J. Burri; Nancy Y. Lee Published: 03/23/2009 Abstract and Introduction Abstract Head and neck cancer is best managed in a multidisciplinary

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

Fighting the Battles: Conducting a Clinical Assay 6 Vocabulary: In Vitro: studies in biology that are conducted using components of an organism that have been isolated from their usual biological surroundings

1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point

Abstract Pancreatic Cancer is the fourth leading cause of cancer death with the lowest survivability. Usually by the time of diagnosis, the cancer has already spread throughout the body and there has not

Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven

Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

Health care and research: Clinical trials in cancer radiotherapy Through its health programmes,the IAEA has initiated co-operative clinical studies to improve the outcome in cancer treatment by Jordanka

Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC

Human Papillomavirus Infection and Oropharyngeal Cancer Robert I. Haddad, MD Introduction Squamous cell carcinoma of the head and neck (SCCHN), which affects close to 40,000 individuals each year in the

CA 125 definitions agreed by GCIG November 2005 The GCIG has agreed criteria for defining response and progression of ovarian carcinoma which use the serum marker CA 125, and the situations where these

What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.

TAXOTERE RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER TAXOTERE -based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer Bridgewater,

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy

Chemotherapy for bladder cancer BCAN Denver September 24, 2011 University of Colorado School of Medicine Founded in 1883 500,000 patients a year 100,00 cancer visits annually Overview Indications for chemotherapy

Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer Shannon Acker April 4, 2011 Rectal Cancer 40,870 new cases in the US in 2009 49,920 deaths from colorectal cancer Second leading cause

FACT SHEET BRANDED/GENERIC NAME: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) ABRAXANE is an albumin-bound form of paclitaxel with a

Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including